LY
Therapeutic Areas
Shenzhen Salubris Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SGLT2 Inhibitor (Innovative NCE) | Type 2 Diabetes Mellitus | Phase III |
| Novel Anti-diabetic Agent (Dual/Triple Agonist) | Type 2 Diabetes Mellitus | Phase II |
| Biosimilar to Bevacizumab | Metastatic Colorectal Cancer, NSCLC | Phase III |
| Biosimilar to Trastuzumab | HER2+ Breast Cancer | Phase III |
| Biosimilar to Rituximab | Non-Hodgkin's Lymphoma, RA | Phase III |
| Novel Anti-coagulant | Stroke Prevention in Atrial Fibrillation | Phase II |
| Novel Anti-inflammatory for COPD | Chronic Obstructive Pulmonary Disease | Phase I/II |
Leadership Team at Shenzhen Salubris Pharmaceuticals
YY
Ye Yucheng
Chairman of the Board
XX
Xu Ximing
General Manager / President
ZX
Zhang Xiaodong
Vice President, Head of R&D